INSIGHT. In recent years, we have seen a clear trend of smaller life science companies hiring contract research organizations, or CROs, to manage their preclinical and clinical studies. This trend is driven, among other things, by increased access to capital for early pharmaceutical companies in recent years. Some of the factors behind this are greater interest and willingness to invest from life science investors, as well as increased government funding.
Carrying out a study through a CRO is generally more expensive than carrying out a study academically, but utilising the specialist expertise of CROs can also result in saving both time and other resources in the end.
The global CRO market is expected to grow from USD 82 billion in 2023 to USD 188 billion in 2030, highlighting the sector’s economic strength and central role in future pharmaceutical research.
About Sciety
Sciety is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Sciety Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations, helping to bring breakthroughs in healthcare to people all over the world. For more information, please visit www.sciety.com and follow us on LinkedIn.
Receive news and invitations from Sciety
Join our newsletter to be the first to know about new investment opportunities and receive invitations to company presentations, seminars, and events.
Disclaimer: The information contained in our emails and communications is intended for informational purposes only and is not intended to constitute advice or recommendations on any investment. We do not guarantee the accuracy, completeness, timeliness, or suitability of any information provided. Please note that our communications are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. In particular, our communications are not intended for persons in the United States or Australia. We do not accept any liability for any loss or damage arising from the use of our communications, including but not limited to any investment decisions made based on the information provided. Furthermore, please note that any investment in private companies involves a high degree of risk and is not suitable for all investors. Before making any investments, you must read and accept our general terms and conditions for investments, which can be found at the following link: General Terms and Conditions for Investments.